

Sector: Biotech & Pharma
Type: Small, private mRNA company
Stage: Clinical
Year Founded: 2013
Number of Employees: 75+




Mission: Expand and apply our proprietary technologies to discover and develop patient-friendly and cost-effective therapies and treatments.



- Series A in 2016: EUR 24 million
- Series B in 2019: EUR 39 million

20 Strategic Partnerships



4 Platforms

1. mRNA Chemistry & Directed Immune Activation
 - a. Optimised mRNA chemistry to shorten production time / throughput
2. Antigen Identification
 - a. investigating validated TAAs in mRNA form
3. Lipid Chemistry & Delivery Formulation
 - a. Extension of lipid libraries
 - b. Novel formulation for different routes of administration
 - c. Targeted delivery
 - d. Additional benefits in improving thermo-stability of final product
4. Process Engineering
 - In house GMP facility
 - Novel DS processes: reduce time and cost and increase yield
 - Novel DP processes: increase reproducibility
 - Novel lyophilisation technology to reduce need for cold chain storage & transport

Differentiators

1. Clinical and preclinical data have demonstrated potential of the proprietary TriMix adjuvant technology to amplify immune responses in multiple disease indications with potential to lower mRNA doses
2. Proprietary formulation platforms enable higher mRNA expression levels and improved biodistribution and safety profiles than comparator formulations
3. Off-the-shelf product strategies, enabled by novel formulation, offer significant time and cost advantages for patients, physicians and payors
4. Novel process technologies promise higher yields and lower costs of goods – important for all indications
5. Novel formulations and process technology combined to improve temperature stability of drug products and overcome supply chain issues see with early approved mRNA vaccines
6. Research collaborations have identified novel antigens for both cancer and infectious disease vaccines
7. Access to China/AsiaPac markets through strategic partnerships
8. Technology and product assets both unencumbered in primary western markets – opportunities for multiple value enhancing partnerships

CONTACT

Europe
 Corporate Headquarters
 Galileilaan 19
 2845 Niel, Belgium
 +32 3 369 17 40
 info@etherna.be

Europe
 Discovery Facilities
 Industriepark Zwijnaarde 7a
 9052 Ghent, Belgium

North America
 1177 Avenue of the
 Americas, 7th floor
 New York, NY 10036
 United States

Asia-Pacific
 Unit 605-07, 6/F Wing on Center
 111 Connaught Road Central
 Sheung Wan, Hong Kong